骨粗鬆症治療薬市場：薬剤タイプ、投与経路、用途別-2025-2030年の世界予測

骨粗鬆症治療薬市場は、2023年に83億2,000万米ドルと評価され、2024年には87億7,000万米ドルに達すると予測され、CAGR 5.60％で成長し、2030年には121億9,000万米ドルに達すると予測されています。

骨粗鬆症治療薬市場は、骨量の減少と骨折リスクの増加を特徴とする骨粗鬆症の治療と予防に主眼を置いています。この市場には、ビスフォスフォネート、選択的エストロゲン受容体モジュレーター（SERM）、副甲状腺ホルモン（PTH）アナログ、モノクローナル抗体など、さまざまな医薬品治療が含まれます。これらの薬剤の必要性は、特に閉経後の女性を中心とした世界の高齢化によって推進されており、骨粗鬆症の治療は生活の質を向上させ、骨折治療に関連するヘルスケアコストを削減するために非常に重要です。適用範囲は病院、クリニック、在宅医療に及び、治療と予防の両方を対象としています。エンドユーザーは主に高齢者、特に閉経年齢を超えた女性です。

市場成長に影響を与える主な要因としては、認知度や診断率の向上、薬剤の処方や投与の進歩、政府のヘルスケア政策の支援などが挙げられます。また、ヘルスケアのインフラが急速に改善しつつある新興市場にもチャンスがあります。副作用が少なく、より簡便な投与レジメンを備えた薬剤の開発は、大きな可能性を秘めています。しかし、高い薬剤費、厳しい規制の枠組み、患者の服薬アドヒアランスを阻害する副作用の可能性など、重大な制約もあります。さらに、地域によってヘルスケア政策や償還の問題が異なることも課題となっています。

成長機会をもたらす革新的研究開発分野としては、併用療法の開発、個別化医療アプローチ、遠隔患者管理のための遠隔医療の統合などが挙げられます。バイオテクノロジーと遺伝子治療の進歩は、新たな治療プラットフォームとして期待されています。市場は、既存の薬剤の副作用を軽減し、有効性を向上させるために、有力企業が研究に多額の投資を行っており、競争的な性質を示しています。企業は、研究開発のための戦略的提携や共同研究、未開拓の地域市場の開拓、市場浸透を高めるための患者教育プログラムの重視などに注力することが推奨されます。また、ドラッグデリバリーシステムの最適化や製剤の安全性プロファイルの向上など、既存の限界に対処することも、市場拡大のために優先されるべきです。

市場力学：急速に進化する骨粗鬆症治療薬市場における主要市場インサイトの解明

骨粗鬆症治療薬市場は、需給要因のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢者人口の増加と骨の健康に影響を与える生活習慣の変化
  • 骨粗鬆症ケアに対する意識の高まりと閉経後女性の骨粗鬆症罹患率
• 市場抑制要因
  • 骨粗鬆症治療薬の特許切れに対する懸念
• 市場機会
  • ヘルスケア機関における製品開発と研究活動の活発化
  • 様々な機関からの研究資金の急増
• 市場の課題
  • 骨粗鬆症治療薬に関連する吐き気、胸焼け、潰瘍などの副作用

ポーターの5つの力骨粗鬆症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：骨粗鬆症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、骨粗鬆症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析骨粗鬆症治療薬市場における競合情勢の把握

骨粗鬆症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス骨粗鬆症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、骨粗鬆症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨骨粗鬆症治療薬市場における成功への道筋を描く

骨粗鬆症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口の増加と生活習慣の変化が骨の健康に影響を及ぼしている
    • 骨粗鬆症ケアの意識向上と閉経後女性の骨粗鬆症発症率
  • 抑制要因
    • 骨粗鬆症治療薬の特許失効に関する懸念
  • 機会
    • ヘルスケア機関における新たな製品開発と調査活動
    • さまざまな組織からの調査資金の増加
  • 課題
    • 骨粗鬆症治療薬に関連する吐き気、胸焼け、潰瘍などの副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 骨粗鬆症治療薬市場薬の種類別

• ビスフォスフォネート
• カルシトニン
• 副甲状腺ホルモン療法
• ランクリガンド阻害剤
• 選択的エストロゲン阻害剤モジュレーター

第7章 骨粗鬆症治療薬市場：投与経路別

• 注射可能
• オーラル

第8章 骨粗鬆症治療薬市場：用途別

• 原発性骨粗鬆症
• 続発性骨粗鬆症

第9章 南北アメリカの骨粗鬆症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の骨粗鬆症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの骨粗鬆症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 骨粗鬆症調査への新たな資金提供を発表
  • WHOとESCEOは、世界の骨粗鬆症と骨折予防に役立つ協力協定を発表しました。
  • FDA、男性の骨粗鬆症治療薬ティムロスを承認
  • イベニティ（ロモソズマブ）が、骨折リスクの高い閉経後女性の重度骨粗鬆症の治療としてCHMPの肯定的見解を取得
  • アムジェン社がホライゾン社を278億米ドルで買収し、希少疾患のパイプラインを拡大。
  • 中外製薬と東和製薬、骨粗鬆症治療薬「エディロール錠」を発売
  • Akums DrugsはMicrocore調査と提携してNESMサプリメントを製造します。
  • ルピン社、日本での閉経後治療薬の臨床試験および販売に関してアイロム社と契約を締結。
  • ファーマノビアはロシュからロカルトロールを買収し、中国での事業を拡大
  • ティムロスの製造元Radius Healthが投資会社に8億9,000万米ドルで売却。
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Alembic Pharmaceuticals Ltd.
• Alkem Laboratories Ltd.
• Amgen, Inc.
• Apotex Inc.
• Century Pharmaceuticals Ltd.
• Cipla Ltd.
• Cubit Healthcare
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• F.Hoffmann La Roche AG
• GlaxoSmithKline PLC
• Hetero Healthcare Ltd.
• Intas Pharmaceuticals Ltd
• Macleods Pharmaceuticals Ltd.
• Merck & Co AG
• Midas Pharma GmbH
• Mylan N.V. by Viatris Inc.
• Natco Pharma Ltd.
• Novartis AG
• Pfizer Inc.
• Polpharma
• Pulse Pharmaceuticals
• Steris Healthcare Pvt. Ltd.
• Sun Pharmaceutical Industries Ltd
• Taj Pharmaceuticals Ltd.
• Teva Pharmaceutical Industries Ltd.
• Vintage Labs Pvt. Ltd.

LIST OF FIGURES

• FIGURE 1. OSTEOPOROSIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. OSTEOPOROSIS DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. OSTEOPOROSIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. OSTEOPOROSIS DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY CALCITONIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PARATHYROID HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY RANK LIGAND INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SELECTIVE ESTROGEN INHIBITORS MODULATOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY PRIMARY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL OSTEOPOROSIS DRUGS MARKET SIZE, BY SECONDARY OSTEOPOROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES OSTEOPOROSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM OSTEOPOROSIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. OSTEOPOROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. OSTEOPOROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Osteoporosis Drugs Market was valued at USD 8.32 billion in 2023, expected to reach USD 8.77 billion in 2024, and is projected to grow at a CAGR of 5.60%, to USD 12.19 billion by 2030.

The market for osteoporosis drugs is primarily focused on the treatment and prevention of osteoporosis, a condition characterized by reduced bone mass and increased fracture risk. This market encompasses a variety of pharmaceutical treatments, including bisphosphonates, selective estrogen receptor modulators (SERMs), parathyroid hormone (PTH) analogs, and monoclonal antibodies. The necessity for these drugs is driven by the global aging population, notably among post-menopausal women, making the treatment of osteoporosis critical for improving quality of life and reducing healthcare costs related to fracture treatment. Application extends across hospitals, clinics, and home healthcare settings, targeting both therapeutic and preventive care. The end-users predominantly are older adults, particularly women beyond the menopausal age.

Key factors influencing market growth include increasing awareness and diagnosis rates, advances in drug formulation and administration, and supportive government healthcare policies. Opportunities also lie in emerging markets where healthcare infrastructure is rapidly improving. The development of drugs with fewer side effects and more convenient dosing regimens presents significant potential. However, significant limitations include high drug costs, stringent regulatory frameworks, and potential side effects that may impede patient adherence. Additionally, varying healthcare policies and reimbursement issues across regions pose challenges.

Innovation and research areas offering growth opportunities include the development of combination therapies, personalized medicine approaches, and the integration of telemedicine for remote patient management. Advances in biotechnology and gene therapy hold the promise of novel treatment platforms. The market exhibits a competitive nature with prominent players investing heavily in research to mitigate the existing drug side effects and improve efficacy. Companies are recommended to focus on strategic alliances and collaborations for R&D, exploring untapped regional markets, and emphasizing patient education programs to enhance market penetration. Addressing the existing limitations by optimizing drug delivery systems and enhancing drug formulation safety profiles should also be prioritized to bolster market expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Osteoporosis Drugs Market

The Osteoporosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising elderly population coupled with changing lifestyle habits impacting bone health
  • Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
• Market Restraints
  • Concerns over patent expiration of osteoporosis drugs
• Market Opportunities
  • Emerging product development and research activities in healthcare organizations
  • Proliferation in the research funding from various organizations
• Market Challenges
  • Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs

Porter's Five Forces: A Strategic Tool for Navigating the Osteoporosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Osteoporosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Osteoporosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Osteoporosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Osteoporosis Drugs Market

A detailed market share analysis in the Osteoporosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Osteoporosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Osteoporosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Osteoporosis Drugs Market

A strategic analysis of the Osteoporosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Osteoporosis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alembic Pharmaceuticals Ltd., Alkem Laboratories Ltd., Amgen, Inc., Apotex Inc., Century Pharmaceuticals Ltd., Cipla Ltd., Cubit Healthcare, Dr. Reddy's Laboratories, Eli Lilly and Company, F.Hoffmann La Roche AG, GlaxoSmithKline PLC, Hetero Healthcare Ltd., Intas Pharmaceuticals Ltd, Macleods Pharmaceuticals Ltd., Merck & Co AG, Midas Pharma GmbH, Mylan N.V. by Viatris Inc., Natco Pharma Ltd., Novartis AG, Pfizer Inc., Polpharma, Pulse Pharmaceuticals, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., and Vintage Labs Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Osteoporosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy, Rank Ligand Inhibitors, and Selective Estrogen Inhibitors Modulator.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on Application, market is studied across Primary Osteoporosis and Secondary Osteoporosis.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising elderly population coupled with changing lifestyle habits impacting bone health
    • 5.1.1.2. Increasing awareness of osteoporosis care and incidence of osteoporosis in postmenopausal women
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns over patent expiration of osteoporosis drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging product development and research activities in healthcare organizations
    • 5.1.3.2. Proliferation in the research funding from various organizations
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects such as nausea, heartburn, and ulcers associated with osteoporosis drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Osteoporosis Drugs Market, by Drug Type

• 6.1. Introduction
• 6.2. Bisphosphonates
• 6.3. Calcitonin
• 6.4. Parathyroid Hormone Therapy
• 6.5. Rank Ligand Inhibitors
• 6.6. Selective Estrogen Inhibitors Modulator

7. Osteoporosis Drugs Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral

8. Osteoporosis Drugs Market, by Application

• 8.1. Introduction
• 8.2. Primary Osteoporosis
• 8.3. Secondary Osteoporosis

9. Americas Osteoporosis Drugs Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Osteoporosis Drugs Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Osteoporosis Drugs Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. New funding for osteoporosis research announced
  • 12.3.2. WHO and ESCEO announce collaborative agreement to benefit global osteoporosis and fracture prevention.
  • 12.3.3. FDA Clears Tymlos for Osteoporosis in Men
  • 12.3.4. EVENITY (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture
  • 12.3.5. Amgen to Acquire Horizon for USD 27.8 Billion, Expanding Rare Disease Pipeline.
  • 12.3.6. Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
  • 12.3.7. Akums Drugs ties up with Microcore Research to manufacture NESM supplements.
  • 12.3.8. Lupin signs agreement with I'rom for clinical trials and marketing of post-menopause drug in Japan.
  • 12.3.9. Pharmanovia expands its footprint in China with the acquisition of Rocaltrol from Roche
  • 12.3.10. Tymlos maker Radius Health sells itself to investment firms for USD 890 Million..
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alembic Pharmaceuticals Ltd.
• 3. Alkem Laboratories Ltd.
• 4. Amgen, Inc.
• 5. Apotex Inc.
• 6. Century Pharmaceuticals Ltd.
• 7. Cipla Ltd.
• 8. Cubit Healthcare
• 9. Dr. Reddy's Laboratories
• 10. Eli Lilly and Company
• 11. F.Hoffmann La Roche AG
• 12. GlaxoSmithKline PLC
• 13. Hetero Healthcare Ltd.
• 14. Intas Pharmaceuticals Ltd
• 15. Macleods Pharmaceuticals Ltd.
• 16. Merck & Co AG
• 17. Midas Pharma GmbH
• 18. Mylan N.V. by Viatris Inc.
• 19. Natco Pharma Ltd.
• 20. Novartis AG
• 21. Pfizer Inc.
• 22. Polpharma
• 23. Pulse Pharmaceuticals
• 24. Steris Healthcare Pvt. Ltd.
• 25. Sun Pharmaceutical Industries Ltd
• 26. Taj Pharmaceuticals Ltd.
• 27. Teva Pharmaceutical Industries Ltd.
• 28. Vintage Labs Pvt. Ltd.